Tadalafil Tablet
Product Images NDC 68071-2632

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-2632). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2632 3)

Label for Tadalafil 20 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets, prescription only (Rx). It includes manufacturer and packager information, barcode, lot, expiration, and serial details, along with storage instructions to keep at controlled temperature 68-77°F and a warning to keep out of reach of children.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg with placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline score. Data points illustrate greater score improvement for Tadalafil 5 mg than placebo, with statistical significance at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs showing blood pressure changes over time (hours) comparing tadalafil versus placebo. The graphs illustrate differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure measured in mmHg over a 96-hour period.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs comparing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing (top graph) and supine (bottom graph) systolic blood pressure over 24 hours post-dose. The y-axes show BP changes in mmHg, and the x-axes represent time in hours after dosing.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil or placebo, each combined with 8 mg qd doxazosin at 08:00. The graph compares 20 mg and 8 mg tadalafil with placebo controls, showing blood pressure fluctuations across time points.*

FDA Label Image

Figure4 (Tadalafil Figure4)

Line graph depicting plasma tadalafil concentration (µg/L) over time (hours) following different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph shows concentration decay over 120 hours with error bars indicating variability.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration. It compares Tadalafil 5 mg and placebo, with Tadalafil demonstrating a greater decrease in score over time. The graph highlights statistical significance at p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The X-axis represents treatment duration in weeks, and the Y-axis represents the change in IPSS score. The graph shows a greater decrease in IPSS score with Tadalafil 5 mg compared to placebo, with statistical significance indicated.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting the least-squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The y-axis shows LS mean change values, and the x-axis shows weeks of therapy at 0, 4, 12, and 26. The graph includes significance indicators for differences between groups.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, depicting its molecular framework with multiple fused rings, including a benzodioxole moiety and several functional groups typical for this PDE5 inhibitor active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.